Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PIK3CA Q1033R PIK3CA H1047R Idelalisib Burkitt lymphoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00084695 Phase II Fludarabine Busulfan + Melphalan anti-thymocyte globulin Cyclophosphamide Prednisone Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Unknown status USA 0
NCT01028716 Phase II Filgrastim + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Fludarabine Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Terminated USA 0
NCT01371630 Phase Ib/II Inotuzumab ozogamicin Cyclophosphamide + Cytarabine + Inotuzumab ozogamicin + Methotrexate + Vincristine Sulfate Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Rituximab Cytarabine + Inotuzumab ozogamicin + Methotrexate Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia Recruiting USA 0
NCT01859819 Phase II Cytarabine + Rituximab Treatment for Advanced B-Cell Lymphoma Completed USA 0
NCT01897012 Phase I Romidepsin Alisertib Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas Completed USA 0
NCT02199184 Phase II Cyclophosphamide + Doxorubicin + Etoposide + Ofatumumab + Prednisone + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine Sulfate Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia Completed USA 0
NCT02393157 Phase II Carboplatin + Etoposide + Ifosfamide + Obinutuzumab Cytarabine Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL (O-ICE) Recruiting USA 0
NCT02532192 Phase I Rituximab Cisplatin Dexamethasone Cytarabine Fluconazole Belinostat A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma Withdrawn 0
NCT02700022 Phase I Alisertib Cyclophosphamide + Doxorubicin + Etoposide + Methylprednisolone + Rituximab + Vincristine Sulfate A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas Terminated USA 0
NCT02701673 Phase Ib/II Azacitidine Pyridoxine Gemcitabine Belinostat Busulfan Melphalan Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma Withdrawn 0
NCT02722668 Phase II Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus anti-thymocyte globulin UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Active, not recruiting USA 0
NCT02797470 Phase Ib/II Carmustine + CCR5 shRNA/TRIM5a/TAR decoy-transduced CD34+ HPCs + Cytarabine + Etoposide + Melphalan Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant Active, not recruiting USA 0
NCT02875002 Phase I Belinostat + Volasertib Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas Withdrawn USA 0
NCT02909777 Phase I CUDC-907 Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma Active, not recruiting USA 0
NCT02950220 Phase I Ibrutinib + Pembrolizumab Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Completed USA 0
NCT03015896 Phase Ib/II Lenalidomide + Nivolumab Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Active, not recruiting USA 0
NCT03085173 Phase I EGFRt/19-28z/4-1BBL CAR T cells A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies Active, not recruiting USA 0
NCT03136146 Phase II Cyclophosphamide Bortezomib Etoposide Rituximab Ofatumumab Clofarabine Pegfilgrastim Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL) Recruiting USA 0
NCT03206671 Phase III Cyclophosphamide + Cytarabine + Dexamethasone + Etoposide + Ifosfamide + Methotrexate + Prednisolone + Rituximab Cyclophosphamide + Cytarabine + Dexamethasone + Etoposide + Ifosfamide + Methotrexate + Prednisolone + Rituximab + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Etoposide + Ifosfamide + Methotrexate + Prednisolone + Rituximab + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Etoposide + Ifosfamide + Methotrexate + Prednisolone + Vincristine Sulfate Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents (B-NHL 2013) Recruiting DEU | AUT 6
NCT03379493 Phase I Study of ET190L1-ARTEMIS T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma Terminated USA 0
NCT03422679 Phase Ib/II CB-103 Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies Terminated USA | FRA | ESP | DEU 2
NCT03610724 Phase II Tisagenlecleucel Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients (BIANCA) Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS 4
NCT03674411 Phase II Busulfan + Filgrastim + Fludarabine + Melphalan + MGTA-456 + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Filgrastim + Fludarabine + MGTA-456 + Mycophenolate mofetil + Tacrolimus Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy Active, not recruiting USA 0
NCT03743246 Phase Ib/II Cyclophosphamide + Fludarabine + Lisocabtagene maraleucel A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) Completed USA | NLD | ITA | FRA | ESP | DEU 0
NCT03793140 Phase II CPI-613 A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations Active, not recruiting USA 0
NCT03833180 Phase I VLS-101 A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies Completed USA 0
NCT04160195 Phase I Cyclophosphamide + Fludarabine Anti-CD19-CD20 CAR T cells T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma Terminated USA 0
NCT04220008 Phase II Busulfan + Clofarabine + Cyclophosphamide + Gemcitabine + Mycophenolate mofetil + Rituximab + Tacrolimus + Vorinostat Busulfan + Clofarabine + Cyclophosphamide + Gemcitabine + Mycophenolate mofetil + Tacrolimus + Vorinostat Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma Withdrawn 0
NCT04285268 Phase II Bortezomib + Rituximab + Venetoclax Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Withdrawn USA 0
NCT04491370 Phase Ib/II Polatuzumab vedotin-piiq Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma Recruiting USA 0
NCT04545762 Phase I Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma Recruiting USA 0
NCT04739813 Phase I Ibrutinib + Lenalidomide + Obinutuzumab + Polatuzumab vedotin-piiq + Prednisone + Venetoclax Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma Recruiting USA 0
NCT04836195 Phase I PCLX-001 Phase I Trial of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma Recruiting CAN 0
NCT04933617 Phase I Copanlisib + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine Sulfate Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas Completed USA 0
NCT05049473 Phase II Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Etoposide + Hydrocortisone + Ifosfamide + Methotrexate + Prednisone + Rituximab + Vincristine Sulfate + Vindesine Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14. Unknown status ESP 0
NCT05206357 Phase I Epcoritamab-bysp Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab Recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS 6
NCT05253495 Phase II Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Hydrocortisone Sodium Succinate + Methotrexate + Rituximab + Vincristine Sulfate Cyclophosphamide + Dexamethasone + Vincristine Sulfate Cytarabine + Etoposide + Polatuzumab vedotin-piiq + Rituximab Cytarabine + Etoposide + Polatuzumab vedotin-piiq Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Hydrocortisone Sodium Succinate + Methotrexate + Polatuzumab vedotin-piiq Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Hydrocortisone Sodium Succinate + Methotrexate + Polatuzumab vedotin-piiq + Rituximab Brentuximab vedotin + Dacarbazine + Doxorubicin + Nivolumab + Rituximab + Vinblastine Brentuximab vedotin + Nivolumab + Rituximab + Vinblastine Brentuximab vedotin + Dacarbazine + Doxorubicin + Nivolumab + Vinblastine Cytarabine + Methotrexate + Rituximab Brentuximab vedotin + Dacarbazine + Doxorubicin + Rituximab + Vinblastine Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma (RADICAL) Recruiting USA 0
NCT05260957 Phase II Mosunetuzumab-axgb + Polatuzumab vedotin-piiq CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL). Recruiting USA 0
NCT05270057 Phase I Cyclophosphamide + Doxorubicin + Etoposide + Loncastuximab tesirine-lpyl + Prednisone + Rituximab + Vincristine Sulfate Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies (LONCA) Recruiting USA 0
NCT05442515 Phase Ib/II CD19/CD22 CAR T cells Cyclophosphamide + Fludarabine CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies Recruiting USA 0
NCT05537766 Phase II Brexucabtagene autoleucel + Cyclophosphamide + Fludarabine Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies (ZUMA-25) Recruiting USA | NLD | ITA | FRA | ESP | DEU | AUT 1
NCT05565417 Phase Ib/II IMT-009 Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas Recruiting USA 0
NCT05702853 Phase Ib/II CD19-CD34 CAR transduced T cells Cyclophosphamide + Fludarabine Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL Recruiting USA 0
NCT05773040 Phase I JV-213 A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas Active, not recruiting USA 0
NCT05797233 Phase I Cyclophosphamide + Fludarabine Anti-CD19-CD20 CAR T cells Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies Recruiting USA 0
NCT06173518 Phase I Obecabtagene autoleucel A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) Recruiting GBR 0
NCT06340737 Phase I Anti-CD22 CAR T cells AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas Recruiting USA 0